Compare Amylx Pharmaceuticals Inc (AMLX) vs Gemini Space Station Inc (GEMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Gemini Space Station Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Gemini Space Station Inc trades at $4.02 (market cap $517.11M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 4.9× Gemini Space Station Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | GEMI | |
|---|---|---|
Market Cap | $2.53B | $517.11M |
Sector | Health | Technology |
52-Week High | $24.19 | $32.52 |
52-Week Low | $7.82 | $3.90 |
Enterprise Value | $2.28B | $507.09M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
GEMI trades at $4.09, up 2.76% today, but remains in a bearish technical trend with support and resistance clustered at $4. The company reported a net loss of $582.81 million in 2025, with negative margins and cash flow from operations, while revenue grew to $179.57 million. Recent news includes a $100 million investment from Winklevoss Capital and multiple securities class action lawsuits filed in May 2026.
The outlook is highly speculative with significant operational losses and legal overhangs, though analyst consensus suggests a $6.33 price target. Investment opportunity hinges on turnaround execution and super app adoption, but risks include persistent unprofitability, competitive pressure, and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →
